<p>Miniaturization of technologies to milli-, micro- and nanoscale offers numerous advantages for diagnostic and therapeutic biomedical applications. In comparison to their macro-scale counterparts, these small-scale systems are more portable, less invasive and less costly. They can facilitate rapid, sensitive and high throughput detection of abnormalities, help track disease progression, reduce sample consumption and improve therapeutic efficacy of drug delivery while decreasing systemic toxicity. Thus, there is clearly a need for creating innovative milli-, micro- and nanoscale tools that can uncover new possibilities in detection and treatment of various types of diseases. The overall objective of this dissertation was to develop novel small-scale technologies that could help enhance diagnostic and/or therapeutic outcomes in patients with cancer, opioid addiction and inflammatory bowel disease. First, we developed an echogenically stable nanodroplet ultrasound contrast agent with potential applications in extravascular molecular imaging of tumors and targeted cancer therapies. Then, we created a polymer blend microsphere system that could be integrated in prescription opioid tablets to develop an abuse-deterrent formulation against smoking. Finally, we designed a release system for localized delivery of aminosalicylates from magnetically actuated millirobots in the colon to improve therapeutic outcomes in patients suffering from inflammatory bowel disease. Overall, the technologies we developed could serve as a basis for designing diagnostic and therapeutic tools that are superior to currently existing platforms.</p>

<p>The use of silicon nanoneedles provides a unique and versatile biointerface for a range of biomedical applications. In this work, we propose a rational design for vertical Si nanoneedles that are printed on a polymer substrate for ocular drug delivery, intracellular recording, and intra-organoid sensing. To enable minimally invasive and long-term sustained delivery of ocular drugs, we integrate vertical Si nanoneedles with a tear-soluble contact lens for ocular drug delivery. We demonstrate the effectiveness of this platform in treating corneal neovascularization in an in vivo rabbit model, surpassing the current gold standard surgical therapy. This platform has the potential to revolutionize the management of various chronic ocular diseases without causing significant side effects.</p> <p>To enable intracellular recording, we present a unique platform consisting of vertical Si nanoneedles coated with a thin, transparent network of Au-Ag nanowires. This platform is held in place and enclosed by a soft, transparent elastomer, providing simultaneous intracellular recording and live imaging with applications in neuroscience, cardiology, muscle physiology, and drug screening. To demonstrate the utility of this platform, we monitored electrical potentials from cardiomyocyte cells and cardiovascular organoids. Additionally, we propose an intra-organoid sensing platform with vertical Si nanoneedles transfer printed into a soft scaffold. This platform can be adjusted and tailored for various organoids and tumor tissues of interest, or used to deliver bioactive molecules of interest into organoids in response to external stimuli.</p> <p>Our proposed designs of vertical Si nanoneedles based platforms demonstrate their significant potential for a broad range of biomedical applications, including ocular drug delivery, intracellular recording, and intraorganoid sensing. These platforms have the potential to revolutionize current approaches and pave the way for future developments in biomedical research and clinical applications, offering new possibilities for the diagnosis and treatment of a wide range of diseases.</p>

<p dir="ltr">Ultra-scaled, always-on, smart, wearable and implantable (WI) therapeutic platforms define the research frontier of modern personalized medicine. The WI platform integrates real-time sensing with on-demand therapy and is ideally suited for real-time management of chronic diseases like diabetes. Traditional blood tracking methods, such as glucometers, are insufficient due to their once-in-a-while measurements and the imprecision of insulin injections, which can lead to severe complications. To address these challenges, researchers have been developing smart and minimally invasive microneedle (MN) components for pain-free glucose detection and drug delivery, potentially functioning as an "artificial pancreas". Inspired by natural body homeostasis, these platforms must be accurate and responsive for immediate corrective interventions. However, artificial MN patches often have slow readings due to factors like MN morphology and composition that remain poorly understood, hindering their optimization and integration into real-time monitoring devices. Despite extensive, iterative experimental efforts worldwide, a holistic framework incorporating the interaction between MN sensing and therapy with fluctuating natural body functions is missing. In this thesis, we propose a generalized framework for glycemic management based on the interaction between biological processes and MN-based operations. The results, incorporating theoretical insights from the 1960s and recent advancements in MN technology, are platform-agnostic. This generality offers a unique template to interpret experimental observations, justify the recent introduction of drugs like GLP-1 cocktails, and optimize platforms for accurate and fast disease management. </p>